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Excretion of Fumonisin B1, Hydrolyzed Fumonisin B1, and the
Fumonisin B1-Fructose Adduct in Rats
Ellen C. Hopmans,† Catherine C. Hauck, Suzanne Hendrich, and Patricia A. Murphy*
Department of Food Science and Human Nutrition, 2312 Food Science Building, Iowa State University,
Ames, Iowa 50011
The excretion of fumonisin B1 (FB1), hydrolyzed FB1 (HFB1), and FB1-fructose addition products
(FB1-fructose) was determined in male Fisher 344/NHsd rats. Rats were dosed by gavage with
0.69, 6.93, or 69.3 ímol/kg of body weight FB1, HFB1, or FB1-fructose. Excretion of unchanged
FB1, HFB1, and HFB1 after hydrolysis was determined in urine and feces by analytical reverse
phase HPLC and fluorometric detection of the o-phthaldialdehyde derivatives. Average total FB1
backbone excretion in feces was 101, 76, and 50% of the dose for FB1, HFB1, and FB1-fructose,
respectively. No effect of dose level was found on the percentage of the dose excreted as total FB1
after hydrolysis. FB1-fructose appears to be absorbed to the highest extent, followed by HFB1.
FB1 appears to be excreted nearly completely in the feces. The greater absorption of HFB1 may
explain the greater toxicity of HFB1 compared to FB1 on a molar basis. However, the detoxification
of FB1 by formation of the fructose adduct cannot be explained by reduced absorption. Average
total FB1 backbone excretion in urine was 2.7, 5.0, and 5.3% of the dose for FB1, HFB1, or FB1-
fructose, respectively.
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INTRODUCTION
Fumonisins are a recently discovered family of myc-
otoxins, produced mainly by the corn pathogens Fusar-
ium moniliforme and Fusarium proliferatum (Marasas,
1996). Gelderblom et al. (1988) first isolated fumonisin
B1 (FB1), the main member of this group of toxins. Its
structure was elucidated by Bezuidenhout et al. (1988).
Equine leukoencephalomalacia, a disease long associ-
ated with the consumption of moldy feed, was repro-
duced in horses by dosing FB1 intravenously or orally
(Marasas et al., 1988; Kellerman et al., 1990). Harrison
et al. (1990) showed that porcine pulmonary edema was
caused by FB1. The fumonisins have been associated
with high human esophageal cancer risk in the Tran-
skei, South Africa (Sydenham et al., 1990; Rheeder et
al., 1992). FB1 was shown to be hepatocarcinogenic and
hepatotoxic in rats by several researchers (Gelderblom
et al., 1991; Voss et al., 1993). Although FB1 is a
complete carcinogen (Gelderblom et al., 1988), the
fumonisins are poor cancer initiators and seemingly lack
genotoxicity (Gelderblom et al., 1992; Norred et al.,
1993). Fumonisins strongly resemble the long-chain
base backbones of sphingolipids, and several researchers
have shown a disruption of sphingolipid biosynthesis
by FB1, both in vitro and in vivo (Wang et al., 1991,
1992; Yoo et al., 1992; Riley et al., 1993; Schroeder et
al., 1994). The importance of this biochemical change
in the diverse toxic effects of fumonisins has not yet been
clearly established.
FB1 has recently been declared a class 2B carcinogen
(IARC, 1993). The presence of fumonisins in corn-
containing foods is a potential risk to human health.
Levels of FB1 ranging from 0 to 2790 íg/g and FB2 levels
ranging from 0 to 1065 íg/g have been found in US corn
foods (Sydenham et al., 1991; Stack and Eppley, 1992;
Hopmans and Murphy, 1993). Additionally, fumonisin
has been found in corn foods in South Africa (Sydenham
et al. (1991), Switzerland (Pittet et al., 1992), Spain
(Sanchis et al., 1994), Italy (Doko and Visconti, 1994),
and Asia (Ueno et al., 1993).
Hydrolyzed FB1 (HFB1), or FB1 backbone, is defined
as FB1 without tricarballylic acid side chains. HFB1 has
been produced when corn was nixtamalized, a tradi-
tional treatment of corn with calcium hydroxide and
heat. In a 4 week feeding study, diethylnitrosamine
(DEN, 15 mg/kg of body weight)-initiated male Fisher
344/N rats were fed corn containing 62-67 ímol/kg of
diet FB1 from F. proliferatum corn culture material, or
fed nixtamalized corn containing 17-25 ímol/kg diet
HFB1, with or without nutrient supplementation (Hen-
drich et al., 1993). Rats receiving nutrient-supple-
mented FB1 or HFB1 diets showed approximately equal
signs of toxicity, such as elevated cholesterol and
glutamate/pyruvate transaminase (GPT) levels and
hepatic adenomas. Although it is possible that other
toxicants were present in these diets prepared with F.
proliferatum corn culture material, it seems likely that
the predominant toxicant was FB1 (Lu et al., 1997), and
after nixtamalization, HFB1. The results suggested that
HFB1 could be more toxic than FB1 itself (Hendrich et
al., 1993), because 17 ímol/kg of diet HFB1 caused toxic
signs approximately equal to 62 ímol FB1/kg of diet in
rats with good nutritional status. Voss et al. (1996)
have confirmed the Hendrich et al. (1993) findings. In
a short-term liver cancer initiation/promotion model,
HFB1 was more cytotoxic than FB1 but was unable to
initiate cancer (Gelderblom et al., 1993). The authors
speculated that HFB1 is poorly absorbed from the gut
and proposed an active role for the tricarballylic acid
side chains in the absorption of fumonisins. HFB1 has
been detected in commercial masa, tortilla chips, and
canned sweet corn (Hopmans and Murphy, 1993).
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The possibility of detoxifying FB1 by derivatizing this
amine with a reducing sugar in the Maillard reaction
was examined because the primary amine in FB1
appears to be crucial for its toxic potential (Kraus et al,
1992) and naturally occurring N-acetyl-FB1 is not toxic
(Gelderblom et al., 1993). The Maillard reaction is a
common reaction in foods between primary amines and
reducing sugars under the influence of heat and might
provide a practical approach to FB detoxification. Mur-
phy et al. (1995) reported that heating 6.93 íM FB1 in
a model system (adapted from Petriella et al. (1988)),
with 100 mM glucose or fructose and 50 mM potassium
phosphate, pH 7.0, resulted in an apparent first-order
loss of reactivity of the FB1 amine with o-phthaldialde-
hyde (OPA). When the reaction mixture was hydro-
lyzed, all of the FB1 was recovered as HFB1. FB1 heated
under identical conditions without a reducing sugar did
not lose reactivity with OPA. The loss of reactivity was
most likely due to the formation of FB1-sugar addition
products. DEN-initiated (15 mg/kg body weight) male
Fisher 344/N rats were fed either 69.3 íM FB1 or 69.3
íMFB1 incubated with fructose (FB1-fructose) diets for
4 weeks. Rats fed FB1 had significantly increased levels
of several markers of hepatocarcinogenicity, while rats
receiving FB1-fructose showed no signs of hepatocar-
cinogenicity (Lu et al., 1997).
The removal of both tricarballylic acid side chains by
hydrolysis or the formation of a fructose adduct is likely
to change the bioavailability of FB1, due to changes in
hydrophobicity, which may help explain the changes in
toxicity observed. HFB1 is a slightly more apolar
molecule than FB1, which could facilitate its absorption
by diffusion across cell membranes. Absorption of the
FB1-fructose adduct was not anticipated as the Mail-
lard reactions typically produces large, polymeric prod-
ucts, and the formation of a fructose adduct appears to
completely detoxify FB1. The objective of this study is
to determine the excretion of FB1, HFB1, and the FB1-
fructose adduct.
MATERIALS AND METHODS
Fumonisin B1 is a class 2B carcinogen (IARC). Its hydroly-
sis product, hydrolyzed FB1, could be a carcinogen. Caution
should be taken during handling of either.
Analytical Standard. FB1 was donated by P. G. Thiel
from the Research Institute for Nutritional Diseases, South
African Medical Research Council, South Africa. All other
reagents were from Fisher Scientific (St. Louis, MO) unless
noted otherwise.
FB1 Purification. FB1 was produced in F. proliferatum
M 5991 liquid culture (Dantzer et al., 1996a). Mycelia were
removed from the liquid culture by filtration before application
of media to a 1 kg XAD-16 column (Sigma, St. Louis, MO).
The column was washed with 3 L water, and FB1 was eluted
with 3 L methanol. The eluant was dried under vacuum at
50 °C, after which the residue was redissolved in water and
loaded onto a Lobar LiChroprep RP-8 column (25  310 mm;
Merck, Darmstadt, Germany). After the mixture was washed
with approximately 300 mL of water:trifluoroacetic acid (TFA)
(1000:1), and 300 mL of water:acetonitrile:TFA (800:200:1),
FB1 was eluted with water:acetonitrile:TFA (500:500:1) and
collected in 15 mL fractions. Fractions were screened for FB1
content by reversed phase TLC (Rottinghaus et al., 1992). FB1-
containing fractions were pooled, concentrated under vacuum
at 50 °C, and applied to a semipreparative C18 column (YMC-
Pack ODS-AM, 10  250 mm, YMC Co., Ltd., Kyoto, Japan).
FB1 was eluted using a linear gradient of water:acetic acid
(1000:1) to acetonitrile:acetic acid (1000:1) in 100 min and a
flow rate of 2 mL/min. FB1-containing fractions, selected by
TLC, were pooled and lyophilized. FB1 and HFB1 purity was
evaluated by measurement of the OPA derivative as described
in Dantzer et al. (1996b).
Preparation of HFB1 and FB1-Fructose. HFB1 was
produced by refluxing 125 ímol of FB1 in 50 mL of 2 N KOH
for 1 h (Hopmans and Murphy, 1993). The reaction mixture
was acidified to pH 4.0 with 2 N HCl and applied to a XAD-16
column (2  35 cm). The column was washed with 100 mL of
water, and HFB1 was eluted with 100 mL of methanol. The
eluant was dried under vacuum at 50 °C and redissolved in
water. FB1-fructose was prepared by heating 125 ímol of FB1
in 1 L of 0.05 M potassium phosphate, 0.10 M fructose, pH
7.0, for 48 h at 80 °C (Murphy et al., 1995). The reaction
mixture was dried under vacuum at 50 °C and redissolved in
water.
Experimental Design. Animal use was approved by the
Iowa State University Animal Care Committee. Male Fisher
344/NHsd rats, 9-10 weeks old, 160-190 g, were dosed by
gavage with 0, 0.69, 6.93, or 69.3 ímol/kg of body weight (BW)
FB1, HFB1, or FB1-fructose (n ) 6). The experiment was
divided in three blocks with two rats of each group per block.
Rats were housed individually in metabolic cages and received
a purified diet, AIN 93M (Reeves et al., 1993), and distilled
water ad lib during the experiment. Rats were weighed
immediately before the initial dose administration and 96 h
after the dose. Food consumption was determined daily.
Urine and feces produced during these time points were
collected at 12, 24, 48, 72, and 96 h after dosing. Urine and
lyophilized feces were stored at -20 °C until analysis.
Sample Preparation. For each time increment, urine was
diluted to 10 mL with water. Five milliliters was acidified to
pH 2.8 with 0.5 N HCl, centrifuged, and cleaned up using C18
solid phase extraction according to Ross et al. (1991). The
remaining 5 mL were refluxed at 100 °C with 5 mL of 2 N
KOH for 2 h, after which the pH was adjusted to 2.8 with 2 N
HCl. The hydrolyzed urine was centrifuged and cleaned up
as above. Urine of rats dosed with HFB1 and all hydrolyzed
urine were eluted from the C18 solid phase extraction car-
tridges with acetonitrile instead of acetonitrile:water (7:3) for
additional recovery.
Extraction of feces, for each time increment, was modified
from Shephard et al. (1992b). Feces were ground using mortar
and pestle. Ground feces were vortexed for 1 min with 10 mL
of 0.1 M EDTA, pH 5.2, centrifuged, and the supernatant
collected. This procedure was repeated a total of nine times.
Half of the combined supernatants was cleaned up using C18
solid phase extraction as above. Before cleanup, fecal extracts
of rats dosed with HFB1 were acidified to pH 2.8 with 2 N
HCl. The C18 solid phase extraction cartridges for these
samples were eluted with acetonitrile. The remaining half of
the combined supernatants was placed in a 100 mL round-
bottom flask and dried under vacuum at 50 °C. The residue
was redissolved in 10 mL of 2 N KOH and refluxed at 100 °C
for 2 h. After adjustment of the pH to 4.0 with 2 N HCl, the
hydrolyzed fecal extracts were centrifuged and applied to a
1.5  5 cm XAD-16 column. The column was washed with 50
mL of water and 50 mL of water:methanol (3:1) and eluted
with 50 mL of methanol. The eluant was dried under vacuum
at 50 °C and redissolved in 5 mL of water:acetonitrile (1:1).
HPLCAnalysis. All urine and fecal extracts were analyzed
before and after hydrolysis. FB1 and HFB1 were detected as
their OPA derivatives following reversed-phase HPLC (Hop-
mans and Murphy, 1993). FB1 and HFB1 were quantified by
comparison of peak areas to a standard curve (0.1-4.5 nmol
of FB1/mL) (Hopmans and Murphy, 1993). All samples were
analyzed in duplicate, and the results were averaged. Limits
of determination were 0.4 nmol of FB1 or HFB1 per urine,
hydrolyzed urine, or fecal sample, and 1.1 nmol of HFB1 per
hydrolyzed fecal sample.
Recoveries. A sample of 138 nmole of FB1, HFB1, or FB1-
fructose was added to control feces or urine (n ) 3). Samples
were spiked 16 h prior to analysis and stored at 4 °C and
analyzed as described above. All results reported were cor-
rected for recovery.
LC-MS. LC-MS analysis of urine containing an unknown
OPA-reactive peak was done according to Thakur and Smith
(1996). A Hewlett-Packard (HP) Series II, 1090A HPLC
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(Hewlett-Packard, Palo Alto, CA) equipped with an HP ODS
hypersil analytical column (100  2.1 mm) and guard column
was used. OPA derivatives were prepared by mixing 25 íL of
urine and 25 íL of fluoraldehyde reagent (premixed OPA
reagent purchased from Pierce Chemical Co., Rockford, IL).
After 1 min the reaction mixture was injected onto the column
and eluted using a linear gradient from 0.1 M ammonium
acetate, pH 3.5:acetonitrile (95:5) to ammonium acetate:
acetonitrile (15:85) in 9 min at 0.8 mL/min. OPA derivatives
were detected using an HP 1046A programmable fluorescence
detector (excitation, 229 nm, emission, 440 nm). Mass analy-
ses were performed using an HP 5989A quadrupole mass
spectrometer connected to the HPLC with an HP Thermospray
(TSP) interface (90:10 split), operated in the filament off,
discharge on, positive ion mode. TSP tip temperature was 192
°C, source temperature was 225 °C, and the quadrupole was
100 °C. Linear scanning was performed betweenm/z 350 and
m/z 650. Data analysis was performed using a Model 59970C
processor.
Sulfatase Enzyme Assay. Urine (200 íL) was dried under
nitrogen and redissolved in 0.9 mL of Tris buffer (0.4 M, pH
7.4). Type VI sulfatase from Aerobacter aerogenes (EC 3.1.6.1)
(Sigma, St. Louis, MO) was diluted using 0.4 M Tris, pH 7.4,
to approximately 1 unit/mL (1 unit hydrolyzes 1.0 ímol of
p-nitrophenyl sulfate per minute at pH 7.1, 37 °C). One-tenth
milliliter diluted enzyme was mixed with the redissolved urine
and incubated at 37 °C for 24 h. The reaction mixture was
acidified to pH 4.0 with 0.5 N HCl and applied to a XAD-16
column (50  5 mm). The column was washed with water and
eluted with methanol. The eluant was dried under vacuum
Figure 1. HPLC chromatogram of the OPA derivatives of (A) urine, (B) hydrolyzed urine, (C) feces, and (D) hydrolyzed feces
from a rat dosed with 69.3 ímol/kg of BW FB1. Retention times for FB1 and HFB1 were 6.0 and 7.0 min.
Table 1. Recovery of FB1, HFB1, and FB1-Fructose from
Urine, Hydrolyzed Urine, Feces, and Hydrolyzed Feces
urine
hydrolyzed
urine feces
hydrolyzed
feces
FB1 88 ( 8a 69 ( 5 79 ( 5 70 ( 5
HFB1 80 ( 7 70 ( 1 47 ( 1 65 ( 8
FB1-fructose 88 ( 8 61 ( 8 79 ( 5 75 ( 18
a Percent of amount added.
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at 50 °C, redissolved in 400 íL of water:acetonitrile (1:1), and
analyzed by HPLC as described above.
Statistical Analysis. Statistical analysis was performed
using the General Linear Models procedure and Student’s
t-test with the SAS package (version 6.03, 1995, Cary, NC).
Differences were considered significant if p e 0.05.
RESULTS AND DISCUSSION
The purification process resulted in 70% pure FB1,
containing traces of FB2 and FB3 but no other primary
amines. Upon alkaline hydrolysis, 99% of the FB1 was
recovered as HFB1. Incubation with 100 mM fructose
at pH 7.0 resulted in an 89 ( 1% loss of OPA reactivity.
Hydrolysis of the reaction mixture resulted in full
recovery (101%) of FB1 as HFB1. The formation of FB1-
fructose addition products reported by Murphy et al.
(1995) was reproduced in this study using 125 mmole
of FB1.
Unchanged FB1 or HFB1, as well as total HFB1 after
hydrolysis, were determined in urine and feces. Meta-
bolic modification of the primary amine would block
reaction with derivatizing reagent, OPA, and prevent
detection of the amine-modified FB1 or HFB1. Hydroly-
sis would remove any such modification, allowing detec-
tion of HFB1. Large differences between unchanged FB1
or HFB1 and total HFB1 could, therefore, indicate
metabolic modification. Figure 1 shows representative
chromatograms of the analysis of urine for FB1, hydro-
lyzed urine for HFB1, feces for FB1, and hydrolyzed fecal
extract for HFB1 of a rat dosed with 69.3 ímol/kg of body
weight (BW) FB1. Table 1 shows recovery of 138 nmol
of FB1, HFB1, or FB1-fructose from control urine,
hydrolyzed urine, feces, and hydrolyzed fecal extract.
All data reported in the following discussion have been
corrected using the recoveries reported in Table 1.
The animals did not experience any adverse health
effects from the fumonisin levels dosed, except for the
rats receiving 69.3 ímol/kg of BW FB1-fructose. These
rats developed diarrhea and gained significantly (p <
0.001) less weight over 4 days, compared to the control
group (average gains of 6 and 18 g, respectively).
Therefore, the 69.3 ímol/kg of BW FB1-fructose group
was excluded from the discussion below. The diarrhea
appeared to be caused by the high fructose content of
the dose (10 g/kg of BW). Rats cannot absorb more than
1.5-2.0 g/kg of BW fructose (Riby et al., 1993).
Weight gains in the fumonisin-dosed groups after 4
days were not statistically different from the controls,
except for the rats receiving 6.93 ímol of FB1-fructose/
kg of BW. This group gained significantly (p < 0.001)
more weight than the controls (average gains of 25 and
18 g, respectively). The additional weight gain of these
rats cannot be explained by the caloric value of the
fructose in the dose (1 g or 4.1 kCal/kg of BW) or by
increased food intake, but probably did not influence the
outcome of this study. Figure 2 shows the excretion of
the 6.93 ímol/kg of BW FB1, HFB1, or FB1-fructose in
urine and feces with time. The excretion patterns
shown in Figure 2 for 6.93 ímol/kg of BW were
representative of the patterns at the other two dose
levels.
After 4 days, 2.3, 0.8, and 0.4%, of the 0.69, 6.93, and
69.3 ímol/kg of BW FB1 dose, respectively, were ex-
creted in the urine as unchanged FB1 (Table 2). After
hydrolysis of the urine, 7.4, 1.2, and 0.5% of the
respective doses were recovered. A significantly (p <
0.02) higher percentage of the 0.69 ímol/kg of BW dose
was recovered in hydrolyzed urine compared to the 6.93
and 69.3 ímol/kg of BW doses. No evidence of amine
metabolism was found at the two higher dose levels,
since there was no significant molar difference between
unchanged FB1 and total HFB1 after hydrolysis. FB1
was almost completely excreted in the feces between 24
and 48 h after dosing. After 4 days, 73, 96, and 78% of
the 0.69, 6.93, and 69.3 ímol/kg dose, respectively, was
excreted in feces as FB1 (Table 2). Recovery of the 0.69,
6.93, and 69.3 ímol/kg doses was 110, 92, and 98% after
hydrolysis of the fecal extracts. Compared across the
three dose levels, there was a significant (p < 0.04)
difference between total HFB1 after hydrolysis and
unchanged FB1 recovered in feces (101 and 82%, re-
spectively).
The difference between unchanged FB1 and total
HFB1 after hydrolysis of the fecal extracts may be due
to modification of FB1 by the gastrointestinal (GI) tract
flora, leaving FB1 unable to react with OPA. An
alternative explanation would be modification of FB1 by
phase I or II metabolism and subsequent excretion of
the metabolites in bile. However, Shephard et al. (1994)
found that only 0.2% of a 10.4 ímol/kg of BW oral dose
Figure 2. Excretion in urine and feces of unchanged FB1 or
HFB1 and total FB1 backbone of 6.93 ímol/kg of body weight
(A) FB1, (B) HFB1, and (C) FB1-fructose.
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of [14C]FB1 was excreted in bile, making this course of
events highly unlikely. Our observations on FB1 excre-
tion in urine and feces were very similar to the results
of two studies by Shephard et al. (1992a,b). Shephard
et al. (1992b) reported that, within 24 h after dosing
rats with 10.4 ímol/kg of BW [14C]FB1, a total of 101%
of the activity was recovered in feces. Over 95% of the
radioactivity in feces was accounted for as unchanged
FB1. Only 0.1% of the dose was recovered in urine as
umetabolized FB1. In an earlier study by Shephard et
al. (1992a), 0.4% of a similar dose of FB1 was recovered
unchanged in urine. Excretion in feces was not deter-
mined by Shephard et al. (1992a).
Different excretion results were obtained by Norred
et al. (1993). Eighty percent of 1 mg of [14C]FB1 was
recovered in feces after 96 h, while excretion of radio-
activity in urine totaled 2-3% after 4 days. No analyti-
cal determination of FB1 was performed to distinguish
unchanged FB1 from possible metabolites. A major
design difference of our study compared with that of
Norred et al. (1993) was that their rats were fasted prior
to dosing. The presence of food in the stomach can make
a considerable difference for bioavailability (Melander,
1983). It appears that fasting increases the absorption
of FB1, since Norred et al. (1993) recovered less of the
dose in feces and more in the urine compared with our
study.
After 4 days, 4.9, 0.4, and 0.1% of the 0.69, 6.93, and
69.3 ímol/kg of BW HFB1 dose were found in urine as
unchanged HFB1 (Table 2). After hydrolysis, 15.1, 1.3,
and 0.2% of the respective doses were recovered. Al-
though the percent of HFB1 recovered in urine after
hydrolysis at the 0.69 ímol/kg of BW dose was not
significantly different from the 6.93 or 69.3 ímol/kg of
BW dose, the trend was similar to excretion of FB1.
A new OPA reactive peak, which eluted slightly before
FB1 and well before HFB1, was seen in chromatograms
(Figure 3A) of urine samples of two rats dosed with 6.93
and 0.69 ímol/kg of BW HFB1, respectively. When
these samples were hydrolyzed, this peak appeared to
convert to HFB1 (Figure 3B). Analysis by LC-MS
identified a mass of 485 units, corresponding to a
sulfated HFB1. In this case, the sulfate could have been
esterified with one of the hydroxyl groups and not the
Table 2. Percent of FB1, HFB1, or FB1-Fructose Dose Recovered in Urine, Hydrolyzed Urine, Feces, and Hydrolyzed
Feces
ímol/kg of BW
FB1 HFB1 FB1-fructose
0.69 6.93 69.3 0.69 6.93 69.3 0.69 6.93
body weight (g) 176a 180 176 179 184 185 177 173
dose (nmol) 122 1247 12197 124 1275 12821 123 1199
urine (%) 2.3 0.8 0.4 4.9 0.4 0.1 8.3 0.2
hydrolyzed urine (%) 7.4a b 1.2b 0.5b 15.1 1.3 0.2 9.8a 0.8b
LSD 8.8 1.4 0.7 27.2 1.0 0.1 18.2 1.0
feces (%) 73x c 96 78 29x 29x 25x 13x 14x
hydrolyzed feces (%) 110y 92 98 103y 60y 72y 58y 39y
LSD 28 48 24 71 26 18 16 14
a Amounts reported were the average of six animals. b Percentages of dose recovered for an individual compound (FB1, HFB1, and
FB1-fructose, respectively) in a row with different superscript (a, b) were significantly different at p e 0.05. LSD for urine: FB1 ) 5.0;
HFB1 ) 16.6; FB1-fructose ) 7.7. LSD for feces: FB1 ) 39; HFB1 ) 46; FB1-fructose ) 22. c Percentages of dose recovered for urine and
hydrolyzed urine or for feces and hydrolyzed feces in a column with different superscripts (x, y) were significantly different at p e 0.05.
Figure 3. Chromatogram of urine of a rat dosed with 6.93 ímol/kg of BWHFB1 showing (A) the new OPA-reactive peak (retention
time 5.5 min) and (B) its conversion to backbone after alkaline hydrolysis (retention time HFB1 7.0 min). Peak at 15 min was
observed in all urine samples including controls.
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primary amine, since the amine was still available for
reaction with OPA. Attempts to confirm the identity
of this possible HFB1-sulfate by enzymatic hydrolysis
using Aerobacter aerogenes sulfatase could not confirm
a sulfate derivative available to enzymatic hydrolysis.
Other attempts at enzymatic modification of FB1 have
led to mixed results (Murphy et al., 1996).
In the fecal extracts, 25, 29, and 29% of the 0.69, 6.93,
and 69.3 ímol of HFB1/kg of BW dose were recovered
as unchanged HFB1 (Table 2). After hydrolysis of the
fecal extract, 103, 60, and 72% were recovered. Com-
pared across the three dose levels, a highly significant
difference (p < 0.0001) was found in fecal extracts
between unchanged HFB1 and total HFB1 after hy-
drolysis after 4 days (28 and 76%, respectively). Two
possible mechanisms could result in more total HFB1
excreted than unchanged HFB1: modification by GI
microorganisms or phase I or II metabolism after
absorption and subsequent excretion in the bile. No
information is available on biliary excretion of HFB1 nor
could this study distinguish between nonabsorbed HFB1
in feces or HFB1 excreted in bile. It is therefore not
possible to conclude whether the modification of HFB1
occurs by one or both mechanisms.
FB1-fructose was measured after alkaline hydrolysis
as HFB1. After hydrolysis, 9.8% of the 0.69 ímol of
FB1-fructose/kg of BW dose and 0.8% of the 6.93 ímol
of FB1-fructose/kg of BW dose were recovered from
urine. Surprisingly, in unhydrolyzed urine, 8.3% of the
lower dose and 0.2% of the higher dose of FB1-fructose
were excreted in urine as intact FB1 (Table 2). There
was no difference (p < 0.05) between the amount
excreted as FB1 or total HFB1 determined after hydroly-
sis at either dose. If the FB1-fructose addition products
were excreted intact, more HFB1 should have been
recovered after hydrolysis than could be accounted for
by FB1. A higher percentage (p < 0.05) of the 0.69 ímol/
kg of BW FB1-fructose dose was excreted in urine after
96 h compared to the 6.93 ímol/kg of BW dose.
FB1-fructose in feces extracts, as FB1, totaled 13 and
14% of the 0.69 and 6.93 ímol/kg of BW doses, respec-
tively, after 4 days (Table 2). Fifty-eight and 39% of
the 0.69 and 6.93 ímol/kg of BW dose, respectively, were
recovered in the fecal extract as HFB1 after hydrolysis.
More total HFB1 was recovered after hydrolysis (p <
0.0001) than unchanged FB1. This shows that intact
FB1-fructose was excreted in feces. Eleven percent of
the FB1, in the original FB1-fructose dose, was unre-
acted. In urine and in feces more than 11% of the total
HFB1 detected after hydrolysis was accounted for by FB1
excreted. Apparently some of the FB1-fructose was
hydrolyzed prior to excretion.
In comparing the three forms of FB1 administered,
no difference was found in the percentage total HFB1
in urine between FB1, HFB1, and FB1-fructose at 0.69
and 6.93 ímol/kg of BW. However, at 69.3 ímol/kg of
BW, more (p < 0.04) total HFB1 was recovered after
dosing with FB1 compared to HFB1. For all three forms
of fumonisin, a higher percentage of the dose was
excreted in urine at the lowest dose, compared to the
two higher levels, although this was not statistically
significant for HFB1. The dose level had no effect on
excretion of total HFB1 in feces for either FB1, HFB1,
or FB1-fructose. The major portion of the dose was
excreted in the feces between 24 and 48 h after dosing
in all cases. More than 100% of the 0.69 ímol/kg of BW
FB1 and HFB1 dose was recovered in urine and feces
combined. The absolute amount of unchanged FB1 or
HFB1 or total HFB1 after hydrolysis in individual
samples at 0.69 ímol of FB1, HFB1, or FB1-fructose/kg
of BW was very small and in many cases close to the
limit of determination. This could have affected the
accuracy of the analytical assay, leading to an artificially
high percentage of the dose apparently recovered in
urine, and a total recovery of over 100% of the dose in
those cases. In contrast, at both dose levels of FB1-
fructose and at 6.93 and 69.3 ímol of HFB1/kg of BW,
far less than 100% of the dose was recovered in feces
and urine combined. One possible explanation for the
effect of dose levels may be binding of HFB1 or FB1-
fructose to fecal matter, thus preventing extraction in
the protocol used here. However, in experiments to
evaluate efficiency of the extraction procedures, at least
16 h transpired between addition of FB1-fructose or
HFB1 to feces and extraction. If binding to fecal
material occurred, the resulting losses would have been
accounted for in the recoveries shown in Table 1 and
used in recovery corrections.
Our data do not support the hypothesis posed by
Gelderblom et al. (1992) that HFB1 is absorbed to a
lesser extent than FB1 or that the tricarballylic acids
play an active role in the absorption of FB1. The two
tricarballylic acids probably do not play a role in FB
absorption, except to modify polarity. The loss of the
two tricarballylic acids would render HFB1 a consider-
ably less polar molecule within the GI tract environ-
ment, possibly facilitating its absorption.
Unexpectedly, FB1-fructose appeared to be absorbed
to the greatest extent. Evidence of active transport of
fructose has been reported by Gracey et al. (1972),
Sigrist-Nelson and Hopfer (1974), and more recently by
Crouzoulon and Korieh (1991). It is therefore possible
that fructose could facilitate absorption of FB1. Several
authors reported partial absorption of fructose-amino
acids produced by the Maillard reactions from the GI
tract, but subsequent incorporation in the liver and
utilization of these amino acids in protein synthesis did
not take place or was severely reduced (Sgarbieri et al.,
1973; Tanaka et al., 1975). We propose that, although
absorption of the FB1-fructose addition products is
greater than the absorption of FB1 itself, the formation
of these products detoxifies FB1 by masking the primary
amine group, leaving the molecule unable to exert its
toxic effects.
Alteration of sphingolipid levels is a sensitive biom-
arker for exposure to FBs (Wang et al., 1992; Riley et
al., 1993). If FB1 is truly masked by the formation of
fructose addition products, sphingolipid ratios should
remain at control value in rats exposed to FB1-fructose.
Therefore, future evaluation of FB1-fructose detoxifi-
cation should include sphingolipid ratios to further
elucidate the mechanism of detoxification. Further
studies on the bioavailability of FB1, HFB1, and FB1-
fructose, using radiolabeled FB1, are needed to deter-
mine the fate of the portion of the FB1, HFB1, and FB1-
fructose doses not accounted for by excretion in urine
or feces.
ABBREVIATIONS USED
FB, fumonisin B; HFB, hydrolyzed fumonisin B; OPA,
o-phthaldialdehyde.
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